Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: A meta-analysis

Medicine (United States)

Volumn 98, Issue 26, 2019, Pages

  Jiang, Shan ^a   Liu, Tiecheng ^a   Hu, Yuxin ^a   Li, Ranwei ^a   Di, Xin ^a   Jin, Xin ^a   Wang, Yanqiao ^a   Wang, Ke ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Glucocorticoids; Meta analysis; Severe community acquired pneumonia

Indexed keywords

GLUCOCORTICOID;

COMMUNITY ACQUIRED INFECTION; HUMAN; META ANALYSIS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

COMMUNITY-ACQUIRED INFECTIONS; GLUCOCORTICOIDS; HUMANS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85069263381     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000016239     Document Type: Article

References (24)

1. Qu JM, Cao B. Guidelines for the diagnosis and treatment of adult community acquired pneumonia in China (2016 Edition). Zhonghua Jie He He Hu Xi Za Zhi 2016;39:241–2.
2. Sibila O, Ferrer M, Agustí C, et al. Corticosteroids as adjunctive treatment in community-acquired pneumonia. Minerva Anestesiol 2014;80:1336–44.
3. Tian XL, Jiang M, Sun XF, et al. The indications for glucocorticoids in treating community-acquired pneumonia in adults: a meta-analysis. Zhonghua Jie He He Hu Xi Za Zhi 2016;39:280–5.
4. Welte T, Torres A, Nathwani D. Clinical and economic burden of community- acquired pneumonia among adults in Europe. Thorax 2012;67:71–9.
5. De Pascale G, Bello G, Antonelli M. Steroids in severe pneumonia: a literature review. Minerva Anestesiol 2011;77:902–10.
6. Moran JL, Graham PL, Rockliff S, et al. Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective. Crit Care 2010;14:R134.
7. Tagami T, Matsui H, Horiguchi H, et al. Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. Eur Respir J 2015;45:463–72.
8. Sibila O, Mortensen EM, Anzueto A, et al. Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia. Eur Respir J 2014;43:36–42.
9. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008;36:1937–49.
10. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015;313:677–86.
11. Gu H, Wang Y, Li W. The application of cochrane risk of bias tools in meta-analysis of RCT. Chinese Circ J 2014;29:147–8.
12. Sabry NA, Omar EE. Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm 2011;2: 73–81.
13. Fernandez-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care 2011;15:R96.
14. Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007;185:249–55.
15. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005;171:242–8.
16. Snijders D, Daniels JM, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010; 181:975–82.
17. Ceccato A, Cilloniz C, Ranzani OT, et al. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A posthoc exploratory analysis of a randomized controlled trial. PLoS One 2017;12:e0178022.
18. Marik P, Kraus P, Sribante J, et al. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 1993;104:389–92.
19. El-Ghamrawy AH, Shokeir MH, Esmat AA. Effects of low-dose hydrocortisone in ICU patients with severe community-acquired pneumonia. Egypt J Chest 2006;55:91–9.
20. Nafae RM, Ragab MI, Amany FM, et al. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc 2013;62:439–45.
21. Fernandez-Botran R, Uriarte SM, Arnold FW, et al. Contrasting inflammatory responses in severe and non-severe community-acquired pneumonia. Inflammation 2014;37:1158–66.
22. Lorenzo M-J, Moret I, Sarria B, et al. Lung inflammatory pattern and antibiotic treatment in pneumonia. Respir Res 2015;16:15.
23. Mueller C, Blum CA, Trummler M, et al. Christ-Crain M. Association of adrenal function and disease severity in community-acquired pneumonia. PLoS One 2014;9:e99518.
24. Ariani F, Liu K, Jing Z, et al. Glucocorticosteroid in treatment of severe pneumonia. Mediators Inflamm 2013;2013:865635.